The effects of diazepam and chronic fluoxetine on models of anxiety differ in female rats depending on their reproductive history

Jodie Pestana,Kelly Kershaw,Bronwyn Graham

DOI: https://doi.org/10.1016/j.psyneuen.2023.106718

IF: 4.693

2024-02-01

Psychoneuroendocrinology

Abstract:Background Pregnancy leads to long-term changes in the neurobiological and hormonal features of anxiety in rats and humans. Yet, treatments for anxiety have mostly been tested in male or virgin female animals only. This study examined the effects of two common anti-anxiety medications, a benzodiazepine and a selective serotonin reuptake inhibitor, in female rats pre- versus post-pregnancy. Methods In Experiment 1, virgin (n=47) and age-matched mother rats 1-month post-weaning (n=50), were injected with diazepam (1.3mg/kg or 1.7mg/kg) or vehicle, during proestrus (high estradiol/progesterone phase) or metestrus (low estradiol/progesterone phase) 30-min prior to the elevated plus maze (EPM). In Experiment 2, virgin (n=25) and mother rats (n=20) were chronically administered fluoxetine (10mg/kg) or vehicle prior to a fear conditioning and extinction protocol, and the EPM. Results Replicating past research, in virgin rats, the low dose of diazepam produced anxiolytic effects in proestrus, but only the high dose was anxiolytic in metestrus. In contrast, both doses of diazepam were anxiolytic irrespective of estrous phase in mothers. Fluoxetine produced anxiogenic effects in virgin rats during extinction and the EPM, but had no effect in mothers. In contrast, fluoxetine increased corticosterone levels post-EPM in mothers, but not virgin rats. Conclusion Reproductive experience alters the dose responsivity and efficacy of common anti-anxiety medications in rats. These findings highlight the importance of considering reproductive status in studies on anxiety in females. Doing so may lead to more effective and evidence-based treatments for women both with and without reproductive history.

neurosciences,endocrinology & metabolism,psychiatry